Top Industry Leaders in the Porokeratosis Market
Latest Porokeratosis Companies Updates:
Aurinia Pharmaceuticals acquires Dermavant Sciences: This June 2023 deal strengthens Aurinia's pipeline with Dermavant's ASN-007, a promising drug for DSPPK, a severe form of porokeratosis.
PharmAust Limited partners with the University of Queensland: This collaboration aims to develop PXT3003, a potential long-term treatment for porokeratosis, with the University's expertise in skin biology and drug development.
Alma Lasers introduces Pixel CO2 laser for porokeratosis treatment: This December 2023 launch offers a minimally invasive option for treating localized porokeratosis lesions.
BioPhotas develops a novel photodynamic therapy system for porokeratosis: This technology utilizes light and photosensitive agents to target and destroy porokeratosis lesions.Companies are exploring the potential of artificial intelligence (AI) for porokeratosis diagnosis and personalized treatment recommendations.
List of Porokeratosis Key companies in the market:
- Angiodynamics, Inc. (U.S.)
- Allergan (Republic of Ireland)
- Alma Lasers (Israel)
- Beiersdorf AG (Germany)
- Biogen (U.S.)
- Biolase Inc. (U.S.)
- Coherent, Inc. (U.S.)
- Coty Inc. (U.S.)
- Cutera (U.S.)
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)